We seek breakthroughs that have the power to change the lives of millions

SV Biotechnology Cells Graphic

We invest in novel science seeking breakthroughs that address critical unmet medical needs, have the potential to change the practice of medicine whilst generating attractive investor returns.

We are venture focused and make initial investments at levels from seed capital through early clinical development stages of truly innovative medicines and platform technologies. We have a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.

SV can transform early science into leading companies and employ a company creation approach to biotech investing with many of these companies being created in house. We always welcome the opportunity to talk to entrepreneurs so please get in touch.

Sv biotech cells

Our investments have led to drugs that have changed lives

  • Lynparza Graphic
    LynparzaFirst FDA approved cancer therapy for patients with a BRCA gene mutation
  • Macugen Graphic
    MacugenFirst FDA approved therapy to control vision loss in patients with wet age-related macular degeneration
  • Entyvio Graphic
    EntyvioFirst FDA approved treatment for ulcerative colitis & Crohn’s disease specifically targeting gut inflammation
  • Blincyto Graphic new
    BlincytoFirst FDA approved bi-specific T-cell engager (BiTE) cancer immunotherapy

Advancing Medicine

Our team of entrepreneurs and investors have supported the generation, development, and application of cutting-edge technologies and scientific discoveries that have advanced medicine, including:

SV Biotech Lab Technician
  • CRISPR technology
  • Biological dark matter
  • Bicyclic peptides
  • VEGF inhibition
  • Tumor-activated immunotherapies
  • Natural killer cell engineering
  • Lentiviral-based gene therapy
  • Aptamer selection (SELEX)
  • Switch pocket kinase inhibition
  • Myeloid cell tuning
  • Immunometabolism
  • PARP inhibition
  • Treg targeting
  • AI supported drug discovery
  • Yeast surface display

The Biotech Team

Biotech Portfolio

Active Investments

Exited Investments (M&A, IPO & Recapitalization)

Our Biotech Funds

Biotech News